न्यूरोएंडोक्राइन ट्यूमर
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
कुठे जायचं
या ट्रायलसाठी भारतात 2 हॉस्पिटल्स रुग्ण घेत आहेत.
रजिस्ट्री सारांश (तांत्रिक)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard of care for patients with well-differentiated metastatic or locally advanced GEP-NETs. It has demonstrated a significant improvement in outcomes compared to Octreotide LAR, both as a first-line and second-line treatment approach, following the results of NETTER-1 and NETTER-2 trials, respectively. ENETS guidelines rec…
Sponsor: टाटा मेमोरियल हॉस्पिटल
ClinicalTrials.gov वर NCT07185672
रजिस्ट्रीवर शेवटचं अपडेट 22 Sep 2025 · आम्ही वाचलं 20 Oct 2026